AP129A - Expression of retrovirus gag protein eukaryotic cells - Google Patents

Expression of retrovirus gag protein eukaryotic cells Download PDF

Info

Publication number: AP129A
Authority: AP; ARIPO
Prior art keywords: cells; gag; precursor protein; recombinant; dna molecule
Prior art date: 1988-06-03

Application number

APAP/P/1989/000126A

Other languages

English (en)

Other versions

AP8900126A0 (en

Inventor

Eric Jacobs

Dirk Gheysen

Original Assignee

Smithkline Biologicals S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-06-03

Filing date

1989-05-22

Publication date

1991-04-17

1989-05-22 Application filed by Smithkline Biologicals S A filed Critical Smithkline Biologicals S A

1989-07-31 Publication of AP8900126A0 publication Critical patent/AP8900126A0/xx

1991-04-17 Application granted granted Critical

1991-04-17 Publication of AP129A publication Critical patent/AP129A/en

Links

210000003527 eukaryotic cell Anatomy 0.000 title claims abstract description 10
241001430294 unidentified retrovirus Species 0.000 title abstract description 6
101710177291 Gag polyprotein Proteins 0.000 title description 19
101710125418 Major capsid protein Proteins 0.000 title description 18
108090000623 proteins and genes Proteins 0.000 claims abstract description 96
239000002243 precursor Substances 0.000 claims abstract description 93
102000004169 proteins and genes Human genes 0.000 claims abstract description 84
108020004511 Recombinant DNA Proteins 0.000 claims abstract description 29
238000000034 method Methods 0.000 claims abstract description 17
210000004027 cell Anatomy 0.000 claims description 106
239000002245 particle Substances 0.000 claims description 88
241000700605 Viruses Species 0.000 claims description 47
102000053602 DNA Human genes 0.000 claims description 27
108091026890 Coding region Proteins 0.000 claims description 23
230000001105 regulatory effect Effects 0.000 claims description 19
206010061598 Immunodeficiency Diseases 0.000 claims description 17
208000029462 Immunodeficiency disease Diseases 0.000 claims description 17
239000003636 conditioned culture medium Substances 0.000 claims description 17
230000007813 immunodeficiency Effects 0.000 claims description 17
229960005486 vaccine Drugs 0.000 claims description 17
210000004962 mammalian cell Anatomy 0.000 claims description 15
241000238631 Hexapoda Species 0.000 claims description 14
208000015181 infectious disease Diseases 0.000 claims description 14
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
241000255777 Lepidoptera Species 0.000 claims description 12
241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 10
230000003612 virological effect Effects 0.000 claims description 10
230000002163 immunogen Effects 0.000 claims description 9
241001465754 Metazoa Species 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
210000002966 serum Anatomy 0.000 claims description 6
108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
230000029302 virus maturation Effects 0.000 claims description 5
241000256248 Spodoptera Species 0.000 claims description 3
210000001124 body fluid Anatomy 0.000 claims description 3
108020005065 3' Flanking Region Proteins 0.000 claims description 2
108020005029 5' Flanking Region Proteins 0.000 claims description 2
101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 claims description 2
241000287828 Gallus gallus Species 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 claims description 2
101150012394 PHO5 gene Proteins 0.000 claims description 2
206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
201000000050 myeloid neoplasm Diseases 0.000 claims description 2
230000029812 viral genome replication Effects 0.000 claims description 2
210000005253 yeast cell Anatomy 0.000 claims description 2
238000012258 culturing Methods 0.000 claims 4
101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 claims 2
241000700618 Vaccinia virus Species 0.000 claims 2
238000003745 diagnosis Methods 0.000 claims 2
108010021809 Alcohol dehydrogenase Proteins 0.000 claims 1
101100480861 Caldanaerobacter subterraneus subsp. tengcongensis (strain DSM 15242 / JCM 11007 / NBRC 100824 / MB4) tdh gene Proteins 0.000 claims 1
101100447466 Candida albicans (strain WO-1) TDH1 gene Proteins 0.000 claims 1
101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 claims 1
101001000154 Schistosoma mansoni Phosphoglycerate kinase Proteins 0.000 claims 1
210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
101150088047 tdh3 gene Proteins 0.000 claims 1
210000003501 vero cell Anatomy 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 58
241000725303 Human immunodeficiency virus Species 0.000 description 37
101710205625 Capsid protein p24 Proteins 0.000 description 31
101710177166 Phosphoprotein Proteins 0.000 description 31
101710149279 Small delta antigen Proteins 0.000 description 31
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 31
102100036352 Protein disulfide-isomerase Human genes 0.000 description 27
239000012634 fragment Substances 0.000 description 24
241000701447 unidentified baculovirus Species 0.000 description 24
BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 21
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
239000000427 antigen Substances 0.000 description 17
108091007433 antigens Proteins 0.000 description 17
102000036639 antigens Human genes 0.000 description 17
241000713311 Simian immunodeficiency virus Species 0.000 description 16
108020004414 DNA Proteins 0.000 description 15
239000013598 vector Substances 0.000 description 15
238000003556 assay Methods 0.000 description 13
238000001262 western blot Methods 0.000 description 13
210000000170 cell membrane Anatomy 0.000 description 12
239000000047 product Substances 0.000 description 12
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
238000002474 experimental method Methods 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
208000030507 AIDS Diseases 0.000 description 9
230000034303 cell budding Effects 0.000 description 9
108091034117 Oligonucleotide Proteins 0.000 description 8
101710182846 Polyhedrin Proteins 0.000 description 8
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 8
229920001184 polypeptide Polymers 0.000 description 8
COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 7
239000000499 gel Substances 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 6
239000004471 Glycine Substances 0.000 description 6
108091005804 Peptidases Proteins 0.000 description 6
239000004365 Protease Substances 0.000 description 6
229920004890 Triton X-100 Polymers 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
238000001493 electron microscopy Methods 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
239000000284 extract Substances 0.000 description 6
238000005755 formation reaction Methods 0.000 description 6
239000012528 membrane Substances 0.000 description 6
-1 pi7 Proteins 0.000 description 6
230000008569 process Effects 0.000 description 6
238000002965 ELISA Methods 0.000 description 5
102100034349 Integrase Human genes 0.000 description 5
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
229920001213 Polysorbate 20 Polymers 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
238000010276 construction Methods 0.000 description 5
239000007771 core particle Substances 0.000 description 5
108700004026 gag Genes Proteins 0.000 description 5
101150098622 gag gene Proteins 0.000 description 5
238000002372 labelling Methods 0.000 description 5
230000007498 myristoylation Effects 0.000 description 5
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000001890 transfection Methods 0.000 description 5
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 4
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 4
101710132601 Capsid protein Proteins 0.000 description 4
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 4
235000021360 Myristic acid Nutrition 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000003599 detergent Substances 0.000 description 4
238000012423 maintenance Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000005199 ultracentrifugation Methods 0.000 description 4
241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 4
108010039627 Aprotinin Proteins 0.000 description 3
206010061818 Disease progression Diseases 0.000 description 3
101710091045 Envelope protein Proteins 0.000 description 3
108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
101710188315 Protein X Proteins 0.000 description 3
210000004102 animal cell Anatomy 0.000 description 3
229960004405 aprotinin Drugs 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000013599 cloning vector Substances 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
239000007857 degradation product Substances 0.000 description 3
230000037433 frameshift Effects 0.000 description 3
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
238000004626 scanning electron microscopy Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000012546 transfer Methods 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 2
KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 2
241001203868 Autographa californica Species 0.000 description 2
241000255789 Bombyx mori Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
208000003322 Coinfection Diseases 0.000 description 2
SWDNPSMMEWRNOH-HJGDQZAQSA-N Glu-Pro-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWDNPSMMEWRNOH-HJGDQZAQSA-N 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
102000003792 Metallothionein Human genes 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
241000713862 Moloney murine sarcoma virus Species 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
241000712907 Retroviridae Species 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
NRCJWSGXMAPYQX-LPEHRKFASA-N Ser-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N)C(=O)O NRCJWSGXMAPYQX-LPEHRKFASA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
241000255993 Trichoplusia ni Species 0.000 description 2
101150050575 URA3 gene Proteins 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
108020000999 Viral RNA Proteins 0.000 description 2
230000002411 adverse Effects 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
244000309464 bull Species 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
101150047047 gag-pol gene Proteins 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
244000052769 pathogen Species 0.000 description 2
108010073101 phenylalanylleucine Proteins 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
108700004029 pol Genes Proteins 0.000 description 2
101150088264 pol gene Proteins 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
108010077112 prolyl-proline Proteins 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
101150090724 3 gene Proteins 0.000 description 1
HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
241000714195 Aids-associated retrovirus Species 0.000 description 1
YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
VBDMWOKJZDCFJM-FXQIFTODSA-N Ala-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N VBDMWOKJZDCFJM-FXQIFTODSA-N 0.000 description 1
JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
CCUAQNUWXLYFRA-IMJSIDKUSA-N Ala-Asn Chemical compound C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O CCUAQNUWXLYFRA-IMJSIDKUSA-N 0.000 description 1
MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 1
YCRAFFCYWOUEOF-DLOVCJGASA-N Ala-Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 YCRAFFCYWOUEOF-DLOVCJGASA-N 0.000 description 1
IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
XPBVBZPVNFIHOA-UVBJJODRSA-N Ala-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@H](C)N)=CNC2=C1 XPBVBZPVNFIHOA-UVBJJODRSA-N 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
DBKNLHKEVPZVQC-LPEHRKFASA-N Arg-Ala-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O DBKNLHKEVPZVQC-LPEHRKFASA-N 0.000 description 1
RWWPBOUMKFBHAL-FXQIFTODSA-N Arg-Asn-Cys Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O RWWPBOUMKFBHAL-FXQIFTODSA-N 0.000 description 1
HPSVTWMFWCHKFN-GARJFASQSA-N Arg-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O HPSVTWMFWCHKFN-GARJFASQSA-N 0.000 description 1
PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
MTYLORHAQXVQOW-AVGNSLFASA-N Arg-Lys-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O MTYLORHAQXVQOW-AVGNSLFASA-N 0.000 description 1
CZUHPNLXLWMYMG-UBHSHLNASA-N Arg-Phe-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 CZUHPNLXLWMYMG-UBHSHLNASA-N 0.000 description 1
SWLOHUMCUDRTCL-ZLUOBGJFSA-N Asn-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N SWLOHUMCUDRTCL-ZLUOBGJFSA-N 0.000 description 1
BZMWJLLUAKSIMH-FXQIFTODSA-N Asn-Glu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BZMWJLLUAKSIMH-FXQIFTODSA-N 0.000 description 1
COWITDLVHMZSIW-CIUDSAMLSA-N Asn-Lys-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O COWITDLVHMZSIW-CIUDSAMLSA-N 0.000 description 1
BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
FYRVDDJMNISIKJ-UWVGGRQHSA-N Asn-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FYRVDDJMNISIKJ-UWVGGRQHSA-N 0.000 description 1
MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 1
XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
CLUMZOKVGUWUFD-CIUDSAMLSA-N Asp-Leu-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O CLUMZOKVGUWUFD-CIUDSAMLSA-N 0.000 description 1
FOXXZZGDIAQPQI-XKNYDFJKSA-N Asp-Pro-Ser-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FOXXZZGDIAQPQI-XKNYDFJKSA-N 0.000 description 1
JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 1
BYLPQJAWXJWUCJ-YDHLFZDLSA-N Asp-Tyr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O BYLPQJAWXJWUCJ-YDHLFZDLSA-N 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
101100422644 Caenorhabditis elegans syx-5 gene Proteins 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
DZSICRGTVPDCRN-YUMQZZPRSA-N Cys-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N DZSICRGTVPDCRN-YUMQZZPRSA-N 0.000 description 1
JLZCAZJGWNRXCI-XKBZYTNZSA-N Cys-Thr-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O JLZCAZJGWNRXCI-XKBZYTNZSA-N 0.000 description 1
PXEGEYISOXISDV-XIRDDKMYSA-N Cys-Trp-Lys Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CS)=CNC2=C1 PXEGEYISOXISDV-XIRDDKMYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
241000255597 Drosophila hydei Species 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241001200922 Gagata Species 0.000 description 1
241000255896 Galleria mellonella Species 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 1
IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
LYCDZGLXQBPNQU-WDSKDSINSA-N Glu-Gly-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O LYCDZGLXQBPNQU-WDSKDSINSA-N 0.000 description 1
IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 description 1
YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 1
MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 1
UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
RJVZMGQMJOQIAX-GJZGRUSLSA-N Gly-Trp-Met Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(O)=O RJVZMGQMJOQIAX-GJZGRUSLSA-N 0.000 description 1
SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
241000255967 Helicoverpa zea Species 0.000 description 1
PGRPSOUCWRBWKZ-DLOVCJGASA-N His-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CN=CN1 PGRPSOUCWRBWKZ-DLOVCJGASA-N 0.000 description 1
VIJMRAIWYWRXSR-CIUDSAMLSA-N His-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 VIJMRAIWYWRXSR-CIUDSAMLSA-N 0.000 description 1
BRQKGRLDDDQWQJ-MBLNEYKQSA-N His-Thr-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O BRQKGRLDDDQWQJ-MBLNEYKQSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
241000829111 Human polyomavirus 1 Species 0.000 description 1
241001135958 Human type D retrovirus Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 1
YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 1
MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 1
LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 1
REPBGZHJKYWFMJ-KKUMJFAQSA-N Leu-Lys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N REPBGZHJKYWFMJ-KKUMJFAQSA-N 0.000 description 1
LHSGPCFBGJHPCY-STQMWFEESA-N Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-STQMWFEESA-N 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
CIOWSLJGLSUOME-BQBZGAKWSA-N Lys-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O CIOWSLJGLSUOME-BQBZGAKWSA-N 0.000 description 1
GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 1
DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
XOQMURBBIXRRCR-SRVKXCTJSA-N Lys-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XOQMURBBIXRRCR-SRVKXCTJSA-N 0.000 description 1
ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 description 1
WINFHLHJTRGLCV-BZSNNMDCSA-N Lys-Tyr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=C(O)C=C1 WINFHLHJTRGLCV-BZSNNMDCSA-N 0.000 description 1
IKXQOBUBZSOWDY-AVGNSLFASA-N Lys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N IKXQOBUBZSOWDY-AVGNSLFASA-N 0.000 description 1
241000255908 Manduca sexta Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 description 1
YYEIFXZOBZVDPH-DCAQKATOSA-N Met-Lys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O YYEIFXZOBZVDPH-DCAQKATOSA-N 0.000 description 1
ZYTPOUNUXRBYGW-YUMQZZPRSA-N Met-Met Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCSC ZYTPOUNUXRBYGW-YUMQZZPRSA-N 0.000 description 1
ILKCLLLOGPDNIP-RCWTZXSCSA-N Met-Met-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ILKCLLLOGPDNIP-RCWTZXSCSA-N 0.000 description 1
BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
108010002311 N-glycylglutamic acid Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108010066427 N-valyltryptophan Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 1
UUWCIPUVJJIEEP-SRVKXCTJSA-N Phe-Asn-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N UUWCIPUVJJIEEP-SRVKXCTJSA-N 0.000 description 1
WPTYDQPGBMDUBI-QWRGUYRKSA-N Phe-Gly-Asn Chemical compound N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O WPTYDQPGBMDUBI-QWRGUYRKSA-N 0.000 description 1
SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
241000235648 Pichia Species 0.000 description 1
VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
UUHXBJHVTVGSKM-BQBZGAKWSA-N Pro-Gly-Asn Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UUHXBJHVTVGSKM-BQBZGAKWSA-N 0.000 description 1
XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 description 1
LGMBKOAPPTYKLC-JYJNAYRXSA-N Pro-Phe-Arg Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(O)=O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 LGMBKOAPPTYKLC-JYJNAYRXSA-N 0.000 description 1
RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 1
DGDCSVGVWWAJRS-AVGNSLFASA-N Pro-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 DGDCSVGVWWAJRS-AVGNSLFASA-N 0.000 description 1
VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical group CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
241001456341 Rachiplusia ou Species 0.000 description 1
101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
208000005074 Retroviridae Infections Diseases 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
NUEHQDHDLDXCRU-GUBZILKMSA-N Ser-Pro-Arg Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NUEHQDHDLDXCRU-GUBZILKMSA-N 0.000 description 1
NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
101150033766 Syn3 gene Proteins 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
IMDMLDSVUSMAEJ-HJGDQZAQSA-N Thr-Leu-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IMDMLDSVUSMAEJ-HJGDQZAQSA-N 0.000 description 1
SCSVNSNWUTYSFO-WDCWCFNPSA-N Thr-Lys-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O SCSVNSNWUTYSFO-WDCWCFNPSA-N 0.000 description 1
XNTVWRJTUIOGQO-RHYQMDGZSA-N Thr-Met-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XNTVWRJTUIOGQO-RHYQMDGZSA-N 0.000 description 1
AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 1
101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
MICFJCRQBFSKPA-UMPQAUOISA-N Trp-Met-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)=CNC2=C1 MICFJCRQBFSKPA-UMPQAUOISA-N 0.000 description 1
OJKVFAWXPGCJMF-BPUTZDHNSA-N Trp-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)N[C@@H](CO)C(=O)O OJKVFAWXPGCJMF-BPUTZDHNSA-N 0.000 description 1
ZNFPUOSTMUMUDR-JRQIVUDYSA-N Tyr-Asn-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZNFPUOSTMUMUDR-JRQIVUDYSA-N 0.000 description 1
WOAQYWUEUYMVGK-ULQDDVLXSA-N Tyr-Lys-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOAQYWUEUYMVGK-ULQDDVLXSA-N 0.000 description 1
SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
BIWVVOHTKDLRMP-ULQDDVLXSA-N Tyr-Pro-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BIWVVOHTKDLRMP-ULQDDVLXSA-N 0.000 description 1
SYFHQHYTNCQCCN-MELADBBJSA-N Tyr-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O SYFHQHYTNCQCCN-MELADBBJSA-N 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 1
IDKGBVZGNTYYCC-QXEWZRGKSA-N Val-Asn-Pro Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(O)=O IDKGBVZGNTYYCC-QXEWZRGKSA-N 0.000 description 1
XXWBHOWRARMUOC-NHCYSSNCSA-N Val-Lys-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XXWBHOWRARMUOC-NHCYSSNCSA-N 0.000 description 1
SJLVYVZBFDTRCG-DCAQKATOSA-N Val-Lys-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N SJLVYVZBFDTRCG-DCAQKATOSA-N 0.000 description 1
PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
LZDNBBYBDGBADK-KBPBESRZSA-N Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 description 1
STTYIMSDIYISRG-UHFFFAOYSA-N Valyl-Serine Chemical compound CC(C)C(N)C(=O)NC(CO)C(O)=O STTYIMSDIYISRG-UHFFFAOYSA-N 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
YHGREDQDBYVEOS-UHFFFAOYSA-N [acetyloxy-[2-(diacetyloxyamino)ethyl]amino] acetate Chemical compound CC(=O)ON(OC(C)=O)CCN(OC(C)=O)OC(C)=O YHGREDQDBYVEOS-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
108010013835 arginine glutamate Proteins 0.000 description 1
108010077245 asparaginyl-proline Proteins 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
108010016616 cysteinylglycine Proteins 0.000 description 1
238000005034 decoration Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
210000001840 diploid cell Anatomy 0.000 description 1
201000010099 disease Diseases 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
108010008671 glycyl-tryptophyl-methionine Proteins 0.000 description 1
108010020688 glycylhistidine Proteins 0.000 description 1
108010050848 glycylleucine Proteins 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000000087 hemolymph Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
108010040030 histidinoalanine Proteins 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
108010012058 leucyltyrosine Proteins 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
108010003700 lysyl aspartic acid Proteins 0.000 description 1
108010009298 lysylglutamic acid Proteins 0.000 description 1
108010064235 lysylglycine Proteins 0.000 description 1
108010054155 lysyllysine Proteins 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
108010085203 methionylmethionine Proteins 0.000 description 1
229960000554 metrizamide Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
210000004898 n-terminal fragment Anatomy 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108010004914 prolylarginine Proteins 0.000 description 1
108010070643 prolylglutamic acid Proteins 0.000 description 1
108010029020 prolylglycine Proteins 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 1
238000004627 transmission electron microscopy Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000024275 uncoating of virus Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000007502 viral entry Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
230000010464 virion assembly Effects 0.000 description 1
230000021887 virion transport Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Zoology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)

APAP/P/1989/000126A 1988-06-03 1989-05-22 Expression of retrovirus gag protein eukaryotic cells AP129A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US20227188A	1988-06-03	1988-06-03

Publications (2)

Publication Number	Publication Date
AP8900126A0 AP8900126A0 (en)	1989-07-31
AP129A true AP129A (en)	1991-04-17

Family

ID=22749175

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1989/000126A AP129A (en)	1988-06-03	1989-05-22	Expression of retrovirus gag protein eukaryotic cells

Country Status (8)

Country	Link
EP (1)	EP0345242A3 (fr)
AP (1)	AP129A (fr)
AU (2)	AU627465B2 (fr)
IL (1)	IL90381A0 (fr)
NZ (1)	NZ229297A (fr)
PT (1)	PT90731A (fr)
WO (1)	WO1991000904A1 (fr)
ZA (1)	ZA894137B (fr)

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2003794C (fr) *	1988-12-01	2000-02-08	Hanne R. Johansen	Expression de proteines de vih dans des cellules de drosophiles
US6174666B1 (en)	1992-03-27	2001-01-16	The United States Of America As Represented By The Department Of Health And Human Services	Method of eliminating inhibitory/instability regions from mRNA
US5786464C1 (en) *	1994-09-19	2012-04-24	Gen Hospital Corp	Overexpression of mammalian and viral proteins
US6290969B1 (en)	1995-09-01	2001-09-18	Corixa Corporation	Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en)	1995-09-01	2003-07-15	Corixa Corporation	Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en)	1995-09-01	2002-10-01	Corixa Corporation	Compounds and methods for diagnosis of tuberculosis
US6534312B1 (en)	1996-02-22	2003-03-18	Merck & Co., Inc.	Vaccines comprising synthetic genes
AU2800797A (en)	1996-04-05	1997-10-29	Chiron Corporation	Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP2298900A1 (fr)	1996-09-17	2011-03-23	Novartis Vaccines and Diagnostics, Inc.	Compositions et procédés de traitement de maladies intracellulaires
US6114148C1 (en) *	1996-09-20	2012-05-01	Gen Hospital Corp	High level expression of proteins
US6544523B1 (en)	1996-11-13	2003-04-08	Chiron Corporation	Mutant forms of Fas ligand and uses thereof
EE9900343A (et) *	1997-02-07	2000-02-15	Merck & Co., Inc.	Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
US6696291B2 (en)	1997-02-07	2004-02-24	Merck & Co., Inc.	Synthetic HIV gag genes
US6261562B1 (en)	1997-02-25	2001-07-17	Corixa Corporation	Compounds for immunotherapy of prostate cancer and methods for their use
DE69838584T2 (de)	1997-08-04	2008-06-26	Cell Genesys, Inc., Foster City	Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6914131B1 (en)	1998-10-09	2005-07-05	Chiron S.R.L.	Neisserial antigens
CA2671261A1 (fr)	1997-11-06	1999-05-20	Novartis Vaccines And Diagnostics S.R.L.	Antigenes de neisseria
WO1999033869A2 (fr)	1997-12-24	1999-07-08	Corixa Corporation	Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
EP1047784B2 (fr)	1998-01-14	2015-03-18	Novartis Vaccines and Diagnostics S.r.l.	Antigenes du neisseria meningitidis
AR020318A1 (es)	1998-03-18	2002-05-08	Corixa Corp	Una molecula polinucleotidica aislada, un polipeptido aislado codificado por dicha molecula, un vector de expresion, una celula huesped transformada, unaproteina de fusion, una composicion farmaceutica y una vacuna que comprenden dicho polipeptido o proteina; metodos para el tratamiento, deteccion,
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
EP2261338A3 (fr)	1998-05-01	2012-01-04	Novartis Vaccines and Diagnostics, Inc.	Antigènes de Neisseria meningitidis et compositions
US6375952B1 (en)	1998-08-07	2002-04-23	University Of Washington	Immunological herpes simplex virus antigens and methods for use thereof
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
ATE386804T1 (de)	1998-10-15	2008-03-15	Novartis Vaccines & Diagnostic	Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
JP2002531129A (ja)	1998-12-08	2002-09-24	コリクサコーポレイション	クラミジア感染の処置および診断のための化合物および方法
EP1961813B1 (fr)	1998-12-16	2011-08-10	Novartis Vaccines and Diagnostics, Inc.	Kinase de type humain dépendant de la cycline (hPNQALRE)
US20020119158A1 (en)	1998-12-17	2002-08-29	Corixa Corporation	Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en)	1998-12-28	2003-06-17	Corixa Corporation	Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7083796B2 (en)	2000-06-20	2006-08-01	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2221600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
US7625859B1 (en)	2000-02-16	2009-12-01	Oregon Health & Science University	HER-2 binding antagonists
US7393823B1 (en)	1999-01-20	2008-07-01	Oregon Health And Science University	HER-2 binding antagonists
EA005140B1 (ru)	1999-04-02	2004-12-30	Корикса Корпорейшн	Соединения и способы для лечения и диагностики рака легкого
US8143386B2 (en)	1999-04-07	2012-03-27	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2000066741A2 (fr)	1999-04-30	2000-11-09	Chiron S.P.A.	Antigenes de neisseria conserves
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
EP1229931A4 (fr)	1999-10-07	2003-05-28	Corixa Corp	Proteines hybrides de mycobacterium tuberculosis
JP2004508801A (ja)	1999-10-29	2004-03-25	カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ	ナイセリア抗原性ペプチド
EP2163626A1 (fr)	1999-11-18	2010-03-17	Novartis Vaccines and Diagnostics, Inc.	Gène humain fgf-21 et produits d'expression génique
PT2289545T (pt)	2000-01-17	2016-09-06	Glaxosmithkline Biologicals Sa	Vacina de omv suplementada contra meningococos
EP1854476A3 (fr)	2000-02-09	2008-05-07	Bas Medical, Inc.	Utilisation de la relaxine pour traiter des maladies associées à la vasoconstriction
IL151097A0 (en)	2000-02-23	2003-04-10	Smithkline Beecham Biolog	Tumour-specific animal proteins
AU2001241738A1 (en)	2000-02-25	2001-09-03	Corixa Corporation	Compounds and methods for diagnosis and immunotherapy of tuberculosis
NZ521531A (en)	2000-02-28	2005-12-23	Chiron S	Heterologous expression of neisserial proteins
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001066595A2 (fr)	2000-03-08	2001-09-13	Chiron Corporation	Gene humain fgf-23 et produits d'expression associes
WO2001081379A2 (fr)	2000-04-21	2001-11-01	Corixa Corporation	Composes et procedes pour le traitement et le diagnostic d'une infection a chlamydia
HU230847B1 (en)	2000-05-19	2018-08-28	Corixa Corp	Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
EP1950297A2 (fr)	2000-05-31	2008-07-30	Novartis Vaccines and Diagnostics, Inc.	Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement
US7700359B2 (en)	2000-06-02	2010-04-20	Novartis Vaccines And Diagnostics, Inc.	Gene products differentially expressed in cancerous cells
WO2003057926A1 (fr)	2002-01-08	2003-07-17	Chiron Corporation	Produits geniques a expression differenciee dans des cellules cancereuses du sein et methodes d'utilisation associees
ES2305087T3 (es)	2000-06-15	2008-11-01	Novartis Vaccines And Diagnostics, Inc.	Polinucleotidos relacionados con el cancer de colon.
AR029540A1 (es)	2000-06-28	2003-07-02	Corixa Corp	COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
US20020165192A1 (en)	2000-09-19	2002-11-07	Kerr William G.	Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en)	2001-09-19	2010-04-06	University Of South Florida	Inhibition of SHIP to enhance stem cell harvest and transplantation
CA2881568C (fr)	2000-10-27	2019-09-24	Novartis Vaccines And Diagnostics, Inc.	Acides nucleiques et proteines derives des groupes de streptocoques a et b
JP2004535765A (ja)	2000-12-07	2004-12-02	カイロンコーポレイション	前立腺癌においてアップレギュレートされた内因性レトロウイルス
GB0107658D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
WO2002081641A2 (fr)	2001-04-06	2002-10-17	Georgetown University	Gene scc-112 et utilisations diagnostique et therapeutique de ce gene
AU2002258728A1 (en)	2001-04-06	2002-10-21	Georgetown University	Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (fr)	2001-04-06	2002-10-17	Georgetown University	Gene brcc2 et ses utilisations diagnostiques et therapeutiques
JP2005504513A (ja)	2001-05-09	2005-02-17	コリクサコーポレイション	前立腺癌の治療及び診断のための組成物及び方法
EP1411770A4 (fr)	2001-07-05	2006-05-10	Chiron Corp	Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
EP2280074A3 (fr)	2001-07-05	2011-06-22	Novartis Vaccines and Diagnostics, Inc.	Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
WO2003039491A2 (fr)	2001-11-09	2003-05-15	Georgetown University	Nouveaux isoformes de l'inhibiteur de la croissance de cellules endotheliales vasculaires
RU2331435C2 (ru)	2001-12-12	2008-08-20	Чирон Срл.	Иммунизация против chlamydia trachomatis
DK2224012T3 (da)	2001-12-17	2013-05-13	Corixa Corp	Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US7026465B2 (en)	2002-02-15	2006-04-11	Corixa Corporation	Fusion proteins of Mycobacterium tuberculosis
AU2003218162B2 (en)	2002-03-15	2009-10-29	The Curators Of The University Of Missouri	Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
EP2093233A1 (fr)	2002-03-21	2009-08-26	Sagres Discovery, Inc.	Nouvelles compositions et nouveaux procédés pour le cancer
US7244565B2 (en)	2002-04-10	2007-07-17	Georgetown University	Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en)	2002-04-10	2006-11-21	Georgetown University	Gene SHINC-2 and diagnostic and therapeutic uses thereof
US20030206916A1 (en)	2002-05-03	2003-11-06	Rush-Presbyterian-St. Luke's Medical Center	Immunogenic peptides
US8518694B2 (en)	2002-06-13	2013-08-27	Novartis Vaccines And Diagnostics, Inc.	Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
DK1523582T3 (da)	2002-07-18	2009-03-02	Univ Washington	Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
UA80447C2 (en)	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
ZA200502612B (en)	2002-10-08	2007-07-25	Rinat Neuroscience Corp	Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
WO2005000194A2 (fr)	2002-10-08	2005-01-06	Rinat Neuroscience Corp.	Procedes permettant de traiter des douleurs post-chirurgicales par administration d'un anticorps dirige contre le facteur de croissance neuronal, et compositions contenant cet anticorps
DK2270048T3 (en)	2002-12-24	2016-01-18	Rinat Neuroscience Corp	Anti-NGF antibodies and methods for their use
US9498530B2 (en)	2002-12-24	2016-11-22	Rinat Neuroscience Corp.	Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en)	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
CN101863930A (zh)	2003-01-06	2010-10-20	科里克萨有限公司	一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
US20040170982A1 (en)	2003-02-14	2004-09-02	Morris David W.	Novel therapeutic targets in cancer
JP2007524362A (ja)	2003-02-14	2007-08-30	サイグレスディスカバリー，インコーポレイテッド	癌における治療ｇｐｃｒ標的
US7767387B2 (en)	2003-06-13	2010-08-03	Sagres Discovery, Inc.	Therapeutic targets in cancer
BRPI0407375A (pt)	2003-02-19	2006-02-07	Rinat Neuroscience Corp	Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
EP2353389B1 (fr)	2003-04-21	2015-11-04	Epeius Biotechnologies Corporation	Compositions permettant de traiter les troubles
US20070178066A1 (en)	2003-04-21	2007-08-02	Hall Frederick L	Pathotropic targeted gene delivery system for cancer and other disorders
US7812116B2 (en)	2003-07-03	2010-10-12	Rush University Medical Center	Immunogenic peptides
US7807646B1 (en)	2003-11-20	2010-10-05	University Of South Florida	SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en)	2003-11-20	2010-07-27	University Of South Florida	SHIP-deficiency to increase megakaryocyte progenitor production
AP2006003670A0 (en)	2003-12-23	2006-06-30	Rinat Neuroscience Corp	Agonist anti-TRKC antibodies and methods using same
JP4792390B2 (ja)	2004-03-29	2011-10-12	株式会社ガルファーマ	新規ガレクチン９改変体タンパク質及びその用途
EP3372614B1 (fr)	2004-04-07	2022-06-08	Rinat Neuroscience Corp.	Méthodes de traitement de la douleur associée au cancer des os par administration d'un antagoniste des facteurs de croissance neuronale
EP2199801B1 (fr)	2004-07-14	2013-05-29	The Regents of The University of California	Biomarqueurs pour la détection précoce du cancer des ovaires
US20060024677A1 (en)	2004-07-20	2006-02-02	Morris David W	Novel therapeutic targets in cancer
MX2007000998A (es)	2004-07-30	2007-07-11	Rinat Neuroscience Corp	Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
WO2006020684A2 (fr)	2004-08-10	2006-02-23	Institute For Multiple Myeloma And Bone Cancer Research	Procedes pour reguler la differenciation et traiter le myelome multiple
NZ553776A (en)	2004-09-22	2010-05-28	Glaxosmithkline Biolog Sa	Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
JP2008530245A (ja)	2005-02-18	2008-08-07	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	尿路病原性菌株由来の抗原
EP1701165A1 (fr)	2005-03-07	2006-09-13	Johannes Dr. Coy	Utilisation thérapeutique et diagnostique de TKTL1, ses inhibiteurs et ses activateurs
WO2006104890A2 (fr)	2005-03-31	2006-10-05	Glaxosmithkline Biologicals Sa	Vaccins destines a lutter contre une infection a chlamydia
EP1865981A2 (fr)	2005-04-07	2007-12-19	Chiron Corporation	Cacna1e dans le diagnostic, la detection et le traitement du cancer
CA2604844A1 (fr)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics, Inc.	Genes associes au cancer
DK2457926T3 (da)	2005-04-29	2015-01-05	Glaxosmithkline Biolog Sa	Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
UY29504A1 (es)	2005-04-29	2006-10-31	Rinat Neuroscience Corp	Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
EP1907425B1 (fr)	2005-07-22	2014-01-08	Y's Therapeutics Co., Ltd.	Anticorps anti-cd26 et methodes d'utilisation de ces derniers
EP3069731A1 (fr)	2005-11-14	2016-09-21	Labrys Biologics Inc.	Antagonistes d'anticorps dirigés contre un peptide associé au gène de la calcitonine et procédés les utilisant
EP2441846A3 (fr)	2006-01-09	2012-07-25	The Regents Of the University of California	Combinaisons immunostimulatrices deTNFRSF, TLR, NLR, RHR, du récepteur purinergique et des agonistes du récepteur de la cytokine utilisées pour les vaccins et en immunothérapie anti-tumorale
US9259463B2 (en)	2006-01-16	2016-02-16	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Chlamydia vaccine
JP2009525319A (ja)	2006-02-02	2009-07-09	ライナットニューロサイエンスコーポレイション	ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
WO2007117657A2 (fr)	2006-04-07	2007-10-18	The Research Foundation Of State University Of New York	Polypeptides du récepteur de la transcobalamine, acides nucléiques et modulateurs associés, procédés d'utilisation associés destinés à moduler la croissance cellulaire et à traiter le cancer et la déficience en cobalamine
CA2652703C (fr)	2006-06-07	2018-08-28	Bioalliance C.V.	Anticorps reconnaissant un epitope contenant un hydrate de carbone du cd-43 et de l'ace exprime sur des cellules cancereuses, et procedes les utilisant
PT2054431E (pt)	2006-06-09	2011-11-03	Novartis Ag	Confórmeros de adesinas bacterianas
EP2586790A3 (fr)	2006-08-16	2013-08-14	Novartis AG	Immunogènes d'Escherischia coli pathogènes des voies urinaires
EP2139447A2 (fr)	2007-03-20	2010-01-06	Harold Brem	Compositions gm-csf cosméceuticales et leurs procédés d'utilisation
DK2170384T3 (en)	2007-07-02	2016-07-25	Etubics Corp	METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
BRPI0822049B1 (pt)	2007-12-17	2021-11-16	Pfizer Limited	Composiqao farmaceutica compreendendo anticorpo antagonista anti-ngf, kit e uso de um anticorpo antingf
HUE026846T2 (en)	2007-12-18	2016-08-29	Bioalliance Cv	Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
EP3023502A1 (fr)	2008-04-10	2016-05-25	Cell Signaling Technology, Inc.	Compositions et procédés pour détecter des mutations egfr dans le cancer
WO2009150623A1 (fr)	2008-06-13	2009-12-17	Pfizer Inc	Traitement de la prostatite chronique
TWI516501B (zh)	2008-09-12	2016-01-11	禮納特神經系統科學公司	Ｐｃｓｋ９拮抗劑類
CN102224254A (zh)	2008-09-23	2011-10-19	哈佛大学校长及研究员协会	Sirt4及其用途
WO2010080985A1 (fr)	2009-01-08	2010-07-15	Dana-Farber Cancer Institute, Inc.	Compositions et procédés pour induire la différenciation du tissu adipeux brun
WO2010086828A2 (fr)	2009-02-02	2010-08-05	Rinat Neuroscience Corporation	Anticorps monoclonaux agonistes anti-trkb
US8568732B2 (en)	2009-03-06	2013-10-29	Novartis Ag	Chlamydia antigens
WO2010118243A2 (fr)	2009-04-08	2010-10-14	Genentech, Inc.	Utilisation d'antagonistes de il-27 pour traiter le lupus
EP3263128A3 (fr)	2009-04-14	2018-01-24	GlaxoSmithKline Biologicals S.A.	Compositions pour l'immunisation contre staphylococcus aureus
WO2010146511A1 (fr)	2009-06-17	2010-12-23	Pfizer Limited	Traitement d'une vessie hyperactive
AU2010272243A1 (en)	2009-07-16	2012-03-08	Novartis Ag	Detoxified Escherichia coli immunogens
US8563261B2 (en)	2009-09-28	2013-10-22	The Trustees Of The University Of Pennsylvania	Method of diagnosing and treating interstitial cystitis
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
JP2013517772A (ja)	2010-01-21	2013-05-20	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	遺伝子発見および標的確認を補助するための状況特異的遺伝子スクリーニングプラットフォーム
BR112012018669A2 (pt)	2010-01-27	2017-09-05	Glaxosmithkline Biologicals Sa	Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
AR080291A1 (es)	2010-02-24	2012-03-28	Rinat Neuroscience Corp	Anticuerpos antagonistas anti receptor de il-7 y procedimientos
GB201003333D0 (en)	2010-02-26	2010-04-14	Novartis Ag	Immunogenic proteins and compositions
JP5932670B2 (ja)	2010-03-11	2016-06-08	ライナットニューロサイエンスコーポレイション	ｐＨ依存性の抗原結合を有する抗体
GB201005625D0 (en)	2010-04-01	2010-05-19	Novartis Ag	Immunogenic proteins and compositions
WO2011133931A1 (fr)	2010-04-22	2011-10-27	Genentech, Inc.	Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire
JP2013533286A (ja)	2010-07-30	2013-08-22	セントルイスユニバーシティ	疼痛を治療する方法
US9539427B2 (en)	2010-11-08	2017-01-10	The Johns Hopkins University	Methods for improving heart function
WO2012075243A2 (fr)	2010-12-01	2012-06-07	The University Of North Carolina At Chapel Hill	Procédés et compositions destinés à cibler des sites de croissance néovasculaire
WO2012072769A1 (fr)	2010-12-01	2012-06-07	Novartis Ag	Epitopes rrgb de pneumocoque et combinaisons de variantes
US10221218B2 (en)	2011-05-10	2019-03-05	The Regents Of The University Of California	Adenovirus isolated from titi monkeys
US9267112B2 (en)	2011-05-10	2016-02-23	The Regents Of The University Of California	Adenovirus isolated from Titi Monkeys
CA2837651A1 (fr)	2011-06-21	2012-12-27	Oncofactor Corporation	Compositions et methodes pour la therapie et le diagnostic du cancer
US20130071375A1 (en)	2011-08-22	2013-03-21	Saint Louis University	Compositions and methods for treating inflammation
WO2013028527A1 (fr)	2011-08-23	2013-02-28	Indiana University Research And Technology Corporation	Compositions et procédés pour traiter le cancer
US9241976B2 (en)	2011-08-29	2016-01-26	The Regents Of The University Of California	Use of HDL-related molecules to treat and prevent proinflammatory conditions
CA2848368C (fr)	2011-09-13	2023-02-14	Dana-Farber Cancer Institute, Inc.	Compositions et procedes pour induction et activite de tissu adipeux brun a l'aide de fndc5
US10378060B2 (en)	2011-10-14	2019-08-13	Dana-Farber Cancer Institute, Inc.	ZNF365/ZFP365 biomarker predictive of anti-cancer response
TWI495644B (zh)	2011-11-11	2015-08-11	Rinat Neuroscience Corp	營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
US9249224B2 (en)	2011-12-22	2016-02-02	Rinat Neuroscience Corp.	Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013093693A1 (fr)	2011-12-22	2013-06-27	Rinat Neuroscience Corp.	Anticorps spécifiques de staphylococcus aureus et leurs utilisations
US8603470B1 (en)	2012-08-07	2013-12-10	National Cheng Kung University	Use of IL-20 antagonists for treating liver diseases
US9605276B2 (en)	2012-08-24	2017-03-28	Etubics Corporation	Replication defective adenovirus vector in vaccination
CA2890483A1 (fr)	2012-11-09	2014-05-15	Robert ARCH	Anticorps specifiques du facteur de croissance b derive des plaquettes, leurs compositions et leurs utilisations
AU2014236208B2 (en)	2013-03-14	2018-07-19	Genvivo, Inc.	Thymidine kinase diagnostic assay for gene therapy applications
AU2014240045A1 (en)	2013-03-15	2015-09-10	Dyax Corp.	Anti-plasma kallikrein antibodies
US20140296139A1 (en)	2013-03-15	2014-10-02	The Regents Of The University Of California	Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
US9428537B2 (en)	2013-03-15	2016-08-30	The Board Of Trustees Of The Leland Stanford Junior University	tRNA derived small RNAs (tsRNAs) involved in cell viability
US20160083698A1 (en)	2013-04-19	2016-03-24	The Regents Of The University Of California	Lone star virus
WO2014181229A2 (fr)	2013-05-07	2014-11-13	Rinat Neuroscience Corp.	Anticorps anti-récepteur du glucagon et leurs procédés d'utilisation
US10231993B2 (en)	2013-06-27	2019-03-19	University Of Washington Through Its Center For Commercialization	Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
CA2953917C (fr)	2013-07-01	2021-10-19	The Research Foundation For The State University Of New York	Inhibition de ship dans le cadre de la lutte contre l'obesite
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
CA2919790C (fr)	2013-08-02	2018-06-19	Pfizer Inc.	Anticorps anti-cxcr4 et conjugues anticorps-medicaments
US9683998B2 (en)	2013-11-13	2017-06-20	Pfizer Inc.	Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
WO2015087187A1 (fr)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anticorps anti-sclérostine
WO2015109212A1 (fr)	2014-01-17	2015-07-23	Pfizer Inc.	Anticorps anti-il-2 et compositions et utilisations de ceux-ci
AU2015230933B2 (en)	2014-03-21	2020-08-13	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10428158B2 (en)	2014-03-27	2019-10-01	Dyax Corp.	Compositions and methods for treatment of diabetic macular edema
EP3134546A4 (fr)	2014-04-24	2017-12-06	Dana-Farber Cancer Institute, Inc.	Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire
WO2015168474A1 (fr)	2014-04-30	2015-11-05	President And Fellows Of Harvard College	Protéines de fusion pour le traitement du cancer et procédés associés
ES2913205T3 (es)	2014-05-13	2022-06-01	Bioatla Inc	Proteínas biológicas activas condicionalmente
WO2015195812A1 (fr)	2014-06-17	2015-12-23	The Research Foundation For The State University Of New York	Inhibition de ship pour l'induction de l'activation de cellules tueuses naturelles
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
DK4074735T3 (da)	2014-08-28	2025-07-14	Bioatla Inc	Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
WO2016036916A1 (fr)	2014-09-03	2016-03-10	Bioatla, Llc	Découverte et production de protéines biologiques conditionnellement actives dans les mêmes cellules hôtes eucaryotes de production
CA2972714A1 (fr)	2014-09-09	2016-03-17	Unum Therapeutics	Recepteurs chimeriques et utilisations de ceux-ci en therapie immunitaire
CA2963091A1 (fr)	2014-10-06	2016-04-14	Dana-Farber Cancer Institute, Inc.	Biomarqueurs a base d'angiopoietine -2 utilises pour la prediction de la reponse de point de controle anti-immunitaire
WO2016057651A1 (fr)	2014-10-09	2016-04-14	Dana-Farber Cancer Institute, Inc.	Schéma posologique d'il-2 variables multiples pour le traitement de troubles immunitaires
TWI595006B (zh)	2014-12-09	2017-08-11	禮納特神經系統科學公司	抗ｐｄ－１抗體類和使用彼等之方法
CN107405399B (zh)	2015-01-02	2022-02-08	武田药品工业株式会社	针对血浆激肽释放酶和因子xii的双特异性抗体
WO2016144673A1 (fr)	2015-03-06	2016-09-15	Dana-Farber Cancer Institute, Inc.	Biomarqueurs pd-l2 prédictifs de réponses d'inhibiteurs de la voie pd-1 dans les cancers oesophagogastriques
WO2016154010A1 (fr)	2015-03-20	2016-09-29	Makidon Paul	Compositions immunogènes pour une utilisation en vaccination contre les bordetella
US9758575B2 (en)	2015-04-06	2017-09-12	Yung Shin Pharmaceutical Industrial Co. Ltd.	Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
TWI703159B (zh)	2015-04-13	2020-09-01	美商輝瑞股份有限公司	Bcma特異性治療性抗體及其用途
AU2016297018B9 (en)	2015-07-21	2022-12-01	Takeda Pharmaceutical Company Limited	A monoclonal antibody inhibitor of factor XIIa
WO2017015334A1 (fr)	2015-07-21	2017-01-26	Saint Louis University	Compositions et méthodes pour diagnostiquer et traiter l'infertilité associée à l'endométriose
US11066481B2 (en)	2015-07-23	2021-07-20	The Regents Of The University Of California	Antibodies to coagulation factor XIa and uses thereof
KR102438650B1 (ko)	2015-08-19	2022-08-31	화이자 인코포레이티드	조직 인자 경로 억제제 항체 및 그의 용도
HRP20211081T1 (hr)	2015-09-15	2021-10-15	Scholar Rock, Inc.	Anti-pro/latentna miostatinska protutijela i njihove uporabe
EP3359651A1 (fr)	2015-10-05	2018-08-15	THE UNITED STATES OF AMERICA, represented by the S	Souche de rotavirus humain g9p[6]et utilisation comme vaccin
AU2016337525B2 (en)	2015-10-16	2022-01-20	The Trustees Of Columbia University In The City Of New York	Compositions and methods for inhibition of lineage specific antigens
US11207393B2 (en)	2015-10-16	2021-12-28	President And Fellows Of Harvard College	Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
CN115636880A (zh)	2015-10-23	2023-01-24	辉瑞有限公司	抗il-2抗体及其组合物和用途
WO2017075037A1 (fr)	2015-10-27	2017-05-04	Scholar Rock, Inc.	Facteurs de croissance amorcés et leurs utilisations
AU2016343978A1 (en)	2015-10-29	2018-05-17	Dana-Farber Cancer Institute, Inc.	Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
CN106699889A (zh)	2015-11-18	2017-05-24	礼进生物医药科技（上海）有限公司	抗pd-1抗体及其治疗用途
KR20250057128A (ko)	2015-12-30	2025-04-28	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
CN109219618B (zh)	2016-01-21	2022-08-09	辉瑞大药厂	针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
WO2017165412A2 (fr)	2016-03-21	2017-09-28	Dana-Farber Cancer Institute, Inc.	Régulateurs de l'expression génique spécifiques à l'état d'épuisement des lymphocytes t et leurs utilisations
AU2017290805B2 (en)	2016-07-01	2023-11-16	Research Development Foundation	Elimination of proliferating cells from stem cell-derived grafts
ES3033182T3 (en)	2016-09-20	2025-07-31	Dana Farber Cancer Inst Inc	Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
US20180119141A1 (en)	2016-10-28	2018-05-03	Massachusetts Institute Of Technology	Crispr/cas global regulator screening platform
US20190345501A1 (en)	2017-02-07	2019-11-14	Massachusetts Institute Of Technology	Methods and compositions for rna-guided genetic circuits
CA3054885A1 (fr)	2017-03-03	2018-09-07	Rinat Neuroscience Corp.	Anticorps anti-gitr et leurs methodes d'utilisation
WO2018167621A1 (fr)	2017-03-16	2018-09-20	Pfizer Inc.	Prototrophie à la tyrosine
CA3059938A1 (fr)	2017-04-14	2018-10-18	Kodiak Sciences Inc.	Anticorps antagonistes du facteur d du complement et leurs conjugues
EP3615570A4 (fr)	2017-04-25	2021-02-24	LBL Biotechnology Inc.	Utilisation d'antagonistes de l'il-20 pour le traitement de maladies oculaires
MY201312A (en)	2017-06-02	2024-02-16	Pfizer	Antibodies specific for flt3 and their uses
GB202209539D0 (en)	2017-06-13	2022-08-10	Bostongene Corp	Systems and methods for identifying cancer treatments from normalized biomarker scores
US20190015473A1 (en)	2017-07-13	2019-01-17	Massachusetts Institute Of Technology	Targeting the hdac2-sp3 complex to enhance synaptic funcation
WO2019016784A1 (fr)	2017-07-21	2019-01-24	Universidade De Coimbra	Anticorps anti-nucléoline
KR102794369B1 (ko)	2017-08-01	2025-04-15	에이비 테라퓨틱스 인코퍼레이티드	이중특이 항체 및 그의 용도
CN111093715A (zh)	2017-09-18	2020-05-01	儿童医院医疗中心	强绝缘子和其在基因递送中的用途
CA3073984A1 (fr)	2017-09-21	2019-03-28	Eucure (Beijing) Biopharma Co., Ltd	Anticorps anti-ctla4 et utilisations associees
EP3692370A2 (fr)	2017-10-04	2020-08-12	OPKO Pharmaceuticals, LLC	Articles et procédés destinés à la thérapie personnalisée du cancer
CA3080120C (fr)	2017-10-27	2023-11-21	New York University	Anticorps anti-galectine-9 et leurs utilisations
EP3713958A4 (fr)	2017-11-24	2021-11-03	Eucure (Beijing) Biopharma Co., Ltd	Anticorps anti-ox40 et leurs utilisations
CN112020518A (zh)	2018-02-01	2020-12-01	辉瑞公司	靶向cd70的嵌合抗原受体
PE20210708A1 (es)	2018-02-01	2021-04-16	Pfizer	Anticuerpos especificos para cd70 y sus usos
JP7448954B2 (ja)	2018-02-21	2024-03-13	ザユニバーシティーオブモンタナ	ジアリールトレハロース化合物及びその使用
EP3755716A4 (fr)	2018-02-23	2021-08-04	Eucure (Beijing) Biopharma Co., Ltd	Anticorps anti-pd-1 et leurs utilisations
WO2019168897A2 (fr)	2018-02-28	2019-09-06	Dana-Farber Cancer Institute, Inc.	Méthodes de traitement du cancer à l'aide de combinaisons d'agents de blocage anti-btnl2 et points de contrôle immunitaires
AU2019228381B2 (en)	2018-02-28	2021-12-16	Pfizer Inc.	IL-15 variants and uses thereof
EP3758737A4 (fr)	2018-03-02	2022-10-12	Kodiak Sciences Inc.	Anticorps anti-il-6 et constructions de fusion et conjugués associés
WO2019169313A1 (fr)	2018-03-02	2019-09-06	The University Of Montana	Composés de tréhalose immunogènes et leurs utilisations
JP7429192B2 (ja)	2018-04-06	2024-02-07	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
KR102602329B1 (ko)	2018-05-23	2023-11-16	화이자 인코포레이티드	Cd3에 특이적인 항체 및 이의 용도
MX2020012607A (es)	2018-05-23	2021-01-29	Pfizer	Anticuerpos especificos para gucy2c y sus usos.
AU2019299439C1 (en)	2018-07-03	2025-06-26	Sotio Biotech, Inc.	Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
EP3823987A4 (fr)	2018-07-20	2022-03-02	Eucure (Beijing) Biopharma Co., Ltd	Anticorps anti-cd40 et leurs utilisations
JP7456638B2 (ja)	2018-08-14	2024-03-27	ソティオ，リミティドライアビリティカンパニー	クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用
CA3110837A1 (fr)	2018-08-28	2020-03-05	Vor Biopharma Inc.	Cellules souches hematopoietiques genetiquement modifiees et utilisations associees
SG11202102335YA (en)	2018-09-12	2021-04-29	Eucure Beijing Biopharma Co Ltd	Anti-tnfrsf9 antibodies and uses thereof
JP7603580B2 (ja)	2018-10-15	2024-12-20	エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド	顆粒球マクロファージコロニー刺激因子に対する抗体及びそれらの使用
SG11202105153RA (en)	2018-11-19	2021-06-29	Biocytogen Pharmaceuticals Beijing Co Ltd	Anti-pd-1 antibodies and uses thereof
WO2020132190A1 (fr)	2018-12-21	2020-06-25	Multitude Inc.	Anticorps spécifiques à muc18
US12084500B2 (en)	2019-01-23	2024-09-10	New York University	Antibodies specific to delta 1 chain of T cell receptor
US12463463B2 (en)	2019-01-28	2025-11-04	Ab Therapeutics, Inc.	Bispecific antibodies and uses thereof
CA3125380A1 (fr)	2019-02-18	2020-08-27	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Animaux non humains genetiquement modifies ayant un locus d'immunoglobuline humanisee
EP3962529A4 (fr)	2019-04-30	2023-11-01	Dana-Farber Cancer Institute, Inc.	Méthodes de traitement du cancer à l'aide de combinaisons d'agents anti-cx3cr1 et d'agents de blocage de points de contrôle immunitaires
US12496340B2 (en)	2019-05-23	2025-12-16	The University Of Montana	Vaccine adjuvants based on TLR receptor ligands
US12205675B2 (en)	2019-07-03	2025-01-21	Bostongene Corporation	Techniques for bias correction in sequence data
WO2021071830A1 (fr)	2019-10-07	2021-04-15	University Of Virginia Patent Foundation	Modulation de vaisseaux lymphatiques dans une maladie neurologique
CA3157509A1 (fr)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Procedes de traitement d'un trouble oculaire
WO2021072244A1 (fr)	2019-10-11	2021-04-15	Beth Israel Deaconess Medical Center, Inc.	Anticorps anti-tn et leurs utilisations
EP4093513A4 (fr)	2020-01-24	2024-05-08	Dana-Farber Cancer Institute, Inc.	Utilisations de biomarqueurs pour améliorer une immunothérapie
US20230067811A1 (en)	2020-01-24	2023-03-02	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
WO2021205325A1 (fr)	2020-04-08	2021-10-14	Pfizer Inc.	Anticorps anti-gucy2c et leurs utilisations
WO2021224850A1 (fr)	2020-05-06	2021-11-11	Crispr Therapeutics Ag	Peptides masques et anticorps anti-ptk7 masqués les comprenant
JP2023529846A (ja)	2020-06-02	2023-07-12	バイオサイトジェンファーマシューティカルズ（ベイジン）カンパニーリミテッド	共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
US20230235007A1 (en)	2020-06-15	2023-07-27	Ming-Che Shih	Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
MX2023000662A (es)	2020-07-17	2023-02-27	Pfizer	Anticuerpos terapeuticos y sus usos.
CA3190227A1 (fr)	2020-07-30	2022-02-03	Pfizer Inc.	Cellules ayant des duplications de genes et leurs utilisations
EP4343004A3 (fr)	2020-10-19	2024-09-11	Dana-Farber Cancer Institute, Inc.	Biomarqueurs germinaux de réponse clinique et de bénéfice d'une thérapie par inhibiteur de point de contrôle immunitaire
WO2022104104A2 (fr)	2020-11-13	2022-05-19	Dana-Farber Cancer Institute, Inc.	Vaccins à cellules de fusion personnalisés
US12254961B2 (en)	2020-12-04	2025-03-18	Bostongene Corporation	Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022159793A2 (fr)	2021-01-25	2022-07-28	Dana-Farber Cancer Institute, Inc.	Procédés et compositions pour identifier un cancer de la prostate neuroendocrinien
JP2024517745A (ja)	2021-04-29	2024-04-23	ボストンジーンコーポレイション	複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
US20240280561A1 (en)	2021-06-08	2024-08-22	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CA3227875A1 (fr)	2021-08-02	2023-02-09	Pfizer Inc.	Vecteurs d'expression ameliores et leurs utilisations
WO2023049933A1 (fr)	2021-09-27	2023-03-30	Sotio Biotech Inc.	Polypeptides récepteurs chimériques en combinaison avec des molécules de métabolisme trans qui réorientent des métabolites de glucose hors de la voie de glycolyse et leurs utilisations thérapeutiques
AU2022388928A1 (en)	2021-11-16	2024-05-16	Sotio Biotech Inc.	Treatment of myxoid/round cell liposarcoma patients
WO2023097119A2 (fr)	2021-11-29	2023-06-01	Dana-Farber Cancer Institute, Inc.	Méthodes et compositions pour moduler riok2
CA3249858A1 (fr)	2022-01-31	2023-08-03	Bostongene Corporation	Techniques d'apprentissage automatique pour cytométrie
WO2023148598A1 (fr)	2022-02-02	2023-08-10	Pfizer Inc.	Prototrophie cystéinique
EP4479080A1 (fr)	2022-02-16	2024-12-25	Dana-Farber Cancer Institute, Inc.	Procédés de diminution de l'alpha-synucléine pathologique à l'aide d'agents qui modulent fndc5 ou des fragments biologiquement actifs de celui-ci
US20240029884A1 (en)	2022-07-15	2024-01-25	Bostongene Corporation	Techniques for detecting homologous recombination deficiency (hrd)
WO2024040207A1 (fr)	2022-08-19	2024-02-22	Sotio Biotech Inc.	Cellules tueuses naturelles (nk) génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec des molécules de trans-métabolisme et leurs utilisations thérapeutiques
WO2024040208A1 (fr)	2022-08-19	2024-02-22	Sotio Biotech Inc.	Cellules immunitaires génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec de multiples molécules du métabolisme trans et leurs utilisations thérapeutiques
WO2024215987A1 (fr)	2023-04-14	2024-10-17	Sotio Biotech Inc.	CELLULES IMMUNITAIRES POUR LE TRAITEMENT DU CANCER EN COMBINAISON AVEC DES CONJUGUÉS IL-15/IL-15Rα
EP4694916A1 (fr)	2023-04-14	2026-02-18	SOTIO Biotech Inc.	Cellules immunitaires modifiées pour le traitement d'un cancer en combinaison avec des agonistes ?? du récepteur il-2/il-15
WO2025030010A1 (fr)	2023-08-01	2025-02-06	Vor Biopharma Inc.	Compositions comprenant des cellules souches hématopoïétiques génétiquement modifiées et leurs méthodes d'utilisation
WO2025034542A1 (fr)	2023-08-04	2025-02-13	Cornell University	Panel de signature génique prédisant une réponse cancéreuse à un blocage de point de contrôle immunitaire et radiothérapie
US20260120879A1 (en)	2023-10-31	2026-04-30	Bostongene Corporation	Machine learning technique for identifying ici responders and non-responders
US20250253011A1 (en)	2024-02-02	2025-08-07	Seven Bridges Genomics Inc.	Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference
WO2025202361A1 (fr)	2024-03-27	2025-10-02	Adcendo Aps	Anticorps anti-gpc1 et leurs utilisations
WO2025202359A1 (fr)	2024-03-27	2025-10-02	Adcendo Aps	Anticorps anti-gpc1 et leurs utilisations
WO2025223455A1 (fr)	2024-04-24	2025-10-30	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Anticorps anti-ptk7/b7h3 et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0230222A1 (fr) *	1986-01-06	1987-07-29	F. Hoffmann-La Roche Ag	Expression du gène gag de HTLV-III

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5931799A (ja) *	1982-08-16	1984-02-20	Science & Tech Agency	Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
US4703008A (en) *	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
NZ217645A (en) *	1985-09-25	1991-11-26	Oncogen	Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
WO1988006185A1 (fr) *	1987-02-11	1988-08-25	Scripps Clinic And Research Foundation	Vecteurs retroviraux d'expression et procedes de production d'antigenes du virus d'hepatite b
IL90048A0 (en) *	1988-04-25	1989-12-15	Merck & Co Inc	Recombinant gag precursor of hiv,its preparation and its use as aids vaccine

1989
- 1989-05-22 AP APAP/P/1989/000126A patent/AP129A/en active
- 1989-05-23 IL IL90381A patent/IL90381A0/xx unknown
- 1989-05-26 NZ NZ229297A patent/NZ229297A/en unknown
- 1989-06-01 ZA ZA894137A patent/ZA894137B/xx unknown
- 1989-06-02 PT PT90731A patent/PT90731A/pt not_active Application Discontinuation
- 1989-06-02 EP EP89870082A patent/EP0345242A3/fr not_active Withdrawn
- 1989-06-30 AU AU37256/89A patent/AU627465B2/en not_active Ceased
- 1989-07-11 WO PCT/US1989/002415 patent/WO1991000904A1/fr not_active Ceased
- 1989-07-11 AU AU43206/89A patent/AU4320689A/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0230222A1 (fr) *	1986-01-06	1987-07-29	F. Hoffmann-La Roche Ag	Expression du gène gag de HTLV-III

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCIENCE (March 28, 1986) Vol. 231, pp. 1580-1584: *

Also Published As

Publication number	Publication date
IL90381A0 (en)	1989-12-15
AP8900126A0 (en)	1989-07-31
PT90731A (pt)	1989-12-29
AU4320689A (en)	1991-02-06
ZA894137B (en)	1990-06-27
EP0345242A3 (fr)	1990-05-30
EP0345242A2 (fr)	1989-12-06
AU627465B2 (en)	1992-08-27
AU3725689A (en)	1991-01-03
WO1991000904A1 (fr)	1991-01-24
NZ229297A (en)	1992-01-29

Publication	Publication Date	Title
AP129A (en)	1991-04-17	Expression of retrovirus gag protein eukaryotic cells
US5643756A (en)	1997-07-01	Fusion glycoproteins
US5580773A (en)	1996-12-03	Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
AU727107B2 (en)	2000-11-30	Hiv envelope polypeptides and vaccine
Wagner et al.	1992	Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine
US6043081A (en)	2000-03-28	Expression vectors encoding recombinant proteins comprising a VPR/VPX virion incorporation domain for targeting into HIV-1 or HIV-2 virions
PL161165B1 (pl)	1993-05-31	Sposób wytwarzania bialek wirusa AIDS PL
Luo et al.	1990	Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells
WO1994028929A1 (fr)	1994-12-22	Polypeptides d'enveloppe du vih
CA2084180A1 (fr)	1993-06-12	Expression d'immunogenes specifiques a l'aide d'antigenes viraux
Luo et al.	1992	Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies.
IL102092A (en)	1996-11-14	Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein
EP0577894B1 (fr)	1998-01-07	Conception, construction et expression de protéines chimériques pour le développement de vaccins et de réactifs diagnostiques
EP0272858A2 (fr)	1988-06-29	Protéines recombinantes d'enveloppe du HIV, produites dans des cellules d'insectes
JPH01500161A (ja)	1989-01-26	Ａｉｄｓの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン
CA2155017C (fr)	2009-06-09	Fonction proteinique vpr et activite de celle-ci
JP5290576B2 (ja)	2013-09-18	修飾されたｈｉｖ−１エンベロープタンパク質
JPH0349686A (ja)	1991-03-04	レトロウイルスｇａｇ蛋白の真核生物細胞における発現
JP2002513381A (ja)	2002-05-08	ＨＴＬＶ―Ｉ感染およびＨＴＬＶ―ＩＩ感染を予防するためのｅｎｖ―糖タンパク質ワクチン
JP3085704B2 (ja)	2000-09-11	ドロソフィラ細胞におけるｈｉｖ蛋白の発現
US6270959B1 (en)	2001-08-07	Human T-cell lymphotropic virus type II envelope protein and human monoclonal antibodies specific therefor
WO1995032000A1 (fr)	1995-11-30	Immunogenes de polyproteines de vih
Halsey	2006	Construction and characterization of chimaeric human immunodefiency virus type 1 subtype C Gag virus-like particles
LV10497B (en)	1995-10-20	A method for obtaining a vaccine comprising polypeptides derived from the HIV-1 virus envelope gene